CRTX
NASDAQCortexyme Inc.
Latest news
25 items- SECCortexyme Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- INSIDERSEC Form 4: Monohon Ted covered exercise/tax liability with 1,640 shares, decreasing direct ownership by 5% to 29,311 units to cover taxes4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- SECSEC Form 10-Q filed by Cortexyme Inc.10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)
- SECCortexyme Inc. filed SEC Form 8-K: Leadership Update8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
- INSIDERSEC Form 4: Monohon Ted covered exercise/tax liability with 1,520 shares, decreasing direct ownership by 5% to 30,951 units to cover taxes4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
- SECCortexyme Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Cortexyme, Inc. (0001662774) (Filer)
- NEWSStocks That Hit 52-Week Lows On ThursdayOn Thursday, 108 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Vodafone Group (NASDAQ:VOD) is the largest company in terms of market cap to set a new 52-week low this morning. Helius Medical Tech (NASDAQ:HSDT) was the smallest company when considering market cap to set a new 52-week low. Bausch Health Companies (NYSE:BHC) saw the most significant move of the companies, as shares traded down 50.27% to reach its new 52-week low. Biofrontera (NASDAQ:BFRI) saw the sharpest rebound, as shares ascended 0.01%, reversing after hiting a new 52-week low. The stocks that set new 52-week lows on Thursday: Vodafone Group (NASDAQ:VOD) shares set a new yearly
- NEWSRecap of Wednesday's Biotech Catalysts - End of The Day SummaryIDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58 thousand shares, closed regular trading session at $15.67. IN8bio (NASDAQ:INAB) provided a clinical update from the ongoing Phase 1 trial of INB-100, an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). IN8bio shares traded in a range of $2.37 to $2.88 on a
- NEWSStocks That Hit 52-Week Lows On WednesdayWednesday saw 83 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Orange (NYSE:ORAN) was the largest firm on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was Reshape Lifesciences (NASDAQ:RSLS). F45 Training Holdings (NYSE:FXLV)'s stock came under the most pressure, trading down 74.98% to reach a new 52-week low. LL Flooring Holdings (NYSE:LL)'s stock rebounded the most, as it traded up 0.0% after dropping to a new 52-week low. The stocks that set new 52-week lows on Wednesday: Snap (NYSE:SNAP) shares moved up 0.1% on Wednesday to hit a new 52-week low of $9.61, drifting up 0.1%. Juniper N
- NEWSCortexyme Corporate Name Change To Quince Therapeutics To Take Effect On August 1, 2022New ticker symbol (NASDAQ:QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (NASDAQ:CRTX) today announced that the company's planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics' go-forward growth strategy and development pipeline plans. Additionally, the company's ticker symbol on the Nasdaq Global Select Market is expected change to "QNCX" effective at the open of market trading on Monday, August 1, 2022. The company's common stock will continue to trade under the ticker symb
- NEWSCortexyme Successfully Completes Phase 1 Single And Multiple Ascending Dose Clinical Trial Of COR588Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company’s lysine gingipain inhibitor in development for the treatment of Alzheimer’s disease and indications with disease pathology associated with the keystone pathogen P. gingivalis. The study was a randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of COR588 in healthy adult participants. Previously announced in March 2022, the S
- PRCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022New ticker symbol (NASDAQ:QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (NASDAQ:CRTX) today announced that the company's planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics' go-forward growth strategy and development pipeline plans. Additionally, the company's ticker symbol on the Nasdaq Global Select Market is expected change to "QNCX" effective at the open of market trading on Monday, August 1, 2022. The company's common stock will continue to trade under the ticker sym
- PRCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company's lysine gingipain inhibitor in development for the treatment of Alzheimer's disease and indications with disease pathology associated with the keystone pathogen P. gingivalis. The study was a randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, an
- NEWSStocks That Hit 52-Week Lows On TuesdayOn Tuesday, 120 companies achieved new lows for the year. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Alphabet (NASDAQ:GOOG). Reshape Lifesciences (NASDAQ:RSLS) was the smallest firm on a market cap basis to set a new 52-week low. Luokung Technology (NASDAQ:LKCO) was the biggest loser of the morning session, as it dropped 41.97% to reach its new 52-week low. First US Bancshares (NASDAQ:FUSB) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. The stocks that set new 52-week lows on Tuesday: Polestar Automotive (NASDAQ:PSNY) stock hit a yearly low of $8.61. The stock was up
- NEWSStocks That Hit 52-Week Lows On MondayOn Monday, 100 companies reached new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Newmont (NYSE:NEM) was the biggest company in terms of market cap to set a new 52-week low. Reshape Lifesciences (NASDAQ:RSLS) was the smallest, in terms of market cap, to set a new 52-week low. Motus GI Hldgs (NASDAQ:MOTS) saw the most pronounced move, as shares traded down 12.67% to hit its new 52-week low. eFFECTOR Therapeutics (NASDAQ:EFTR) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. Stocks dropping to new 52-week lows on Monday: Newmont (NYSE:NEM) shares hit a yearly low of $45.91. The stock was down
- SECCortexyme Inc. filed SEC Form 8-K: Leadership Update8-K - Cortexyme, Inc. (0001662774) (Filer)
- NEWSStocks That Hit 52-Week Lows On FridayOn Friday, 137 stocks made new 52-week lows. Interesting Points From Today's 52-Week Lows: Rio Tinto (NYSE:RIO) is the largest company in terms of market cap to set a new 52-week low this morning. First Wave BioPharma (NASDAQ:FWBI) was the smallest company when considering market cap to set a new 52-week low. Codexis (NASDAQ:CDXS)'s stock dropped the most, trading down 42.09% to reach a new 52-week low. TripAdvisor (NASDAQ:TRIP) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. The following stocks created new 52-week lows on Friday: Rio Tinto (NYSE:RIO) stock dropped to a yearly low on Friday of $53.83. Shares traded up 0.93%. Mitsubishi UFJ
- 13D/GSEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
- INSIDERSEC Form 4 filed by Monohon Ted4 - Cortexyme, Inc. (0001662774) (Issuer)
- NEWSStocks That Hit 52-Week Lows On ThursdayOn Thursday, 588 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the biggest company by market cap to set a new 52-week low. Reshape Lifesciences (NASDAQ:RSLS) was the smallest, in terms of market cap, to set a new 52-week low. Akerna (NASDAQ:KERN)'s stock fell the most, as it traded down 52.33% to reach a new 52-week low. Natura &Co Holding (NYSE:NTCO) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. These stocks set new 52-week lows on Thursday: Taiwan Semiconductor (NYSE:TSM) shares moved down 3.16% on Thursday to hit a new 52-week low of $80.12, drifting
- NEWSStocks That Hit 52-Week Lows On WednesdayDuring Wednesday's session, 340 companies made new 52-week lows. Significant Points From Today's 52-Week Lows: NVIDIA (NASDAQ:NVDA) is the largest company in terms of market cap to set a new 52-week low this morning. The company with the smallest market cap to set a new 52-week low was Reshape Lifesciences (NASDAQ:RSLS). Shopify (NYSE:SHOP)'s stock came under the most pressure, trading down 90.56% to reach a new 52-week low. 8x8 (NYSE:EGHT)'s stock showed potential to rebound, rebounding up 0.0% after reaching a new 52-week low. Stocks that set new 52-week lows on Wednesday are as follows: NVIDIA (NASDAQ:NVDA) stock hit a new 52-week low of $151.70. The stock was down 3.74% on
- NEWSStocks That Hit 52-Week Lows On FridayOn Friday, 61 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: Ecopetrol (NYSE:EC) was the biggest company in terms of market cap to set a new 52-week low. ThermoGenesis Holdings (NASDAQ:THMO) was the smallest company in terms of market cap to set a new 52-week low. Quotient (NASDAQ:QTNT)'s stock dropped the most, trading down 31.75% to reach a new 52-week low. Natures Sunshine Products (NASDAQ:NATR)'s stock bounced back the most, actually rising 0.09% after reaching its new 52-week low. The following stocks achieved new 52-week lows on Friday: Ecopetrol (NYSE:EC) shares moved up 3.56% on Friday to hit a new 52-week low of $10.78, drifting up 3.56%
- NEWSStocks That Hit 52-Week Lows On WednesdayOn Wednesday, 329 companies hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Home Depot (NYSE:HD). The smallest company by market cap to hit a new 52-week low was Performance Shipping (NASDAQ:PSHG). Athira Pharma (NASDAQ:ATHA)'s stock made the biggest move downwards, diving 66.66% to reach a new 52-week low. ASA Gold & Precious Metal (NYSE:ASA)'s stock rebounded the most, as it traded up 0.0% after dropping to a new 52-week low. Here are all the stocks that set new 52-week lows on Wednesday: Home Depot (NYSE:HD) stock hit a yearly low of $264.54. The stock was up 0.15% for the day. Walt Disney (
- NEWSCortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus InfectionsCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company's 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after oral treatment. COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cy
- PRCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsCortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company's 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after oral treatment. COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition. 3CLpro, or Mpro, is a validated antiviral drug target shown to be essential in viral r
CRTX FAQ
7 questionsWhat does Cortexyme Inc. do?
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Where does CRTX stock trade?
Cortexyme Inc. (CRTX) is listed on NASDAQ.What sector and industry is CRTX in?
Cortexyme Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Cortexyme Inc. go public?
Cortexyme Inc. (CRTX) completed its IPO in 2019.What are analysts saying about CRTX?
Cortexyme Inc. has had 8 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $1500.00 price target on 2022-03-09. Recent price targets range from $1200.00 to $3000.00.What companies are similar to CRTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CRTX side-by-side with any of them on Quantisnow.How can I track CRTX on Quantisnow?
Quantisnow aggregates Cortexyme Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRTX to receive live email and push alerts on every new disclosure.